Nature Communications (Oct 2021)
Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma
- Claire Vinel,
- Gabriel Rosser,
- Loredana Guglielmi,
- Myrianni Constantinou,
- Nicola Pomella,
- Xinyu Zhang,
- James R. Boot,
- Tania A. Jones,
- Thomas O. Millner,
- Anaelle A. Dumas,
- Vardhman Rakyan,
- Jeremy Rees,
- Jamie L. Thompson,
- Juho Vuononvirta,
- Suchita Nadkarni,
- Tedani El Assan,
- Natasha Aley,
- Yung-Yao Lin,
- Pentao Liu,
- Sven Nelander,
- Denise Sheer,
- Catherine L. R. Merry,
- Federica Marelli-Berg,
- Sebastian Brandner,
- Silvia Marino
Affiliations
- Claire Vinel
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Gabriel Rosser
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Loredana Guglielmi
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Myrianni Constantinou
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Nicola Pomella
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Xinyu Zhang
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- James R. Boot
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Tania A. Jones
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Thomas O. Millner
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Anaelle A. Dumas
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Vardhman Rakyan
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Jeremy Rees
- Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust
- Jamie L. Thompson
- Stem Cell Glycobiology Group, Biodiscovery Institute, University of Nottingham
- Juho Vuononvirta
- The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Suchita Nadkarni
- The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Tedani El Assan
- Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust
- Natasha Aley
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology
- Yung-Yao Lin
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Pentao Liu
- Faculty of Medicine, School of Biomedical Sciences, The University of Hong Kong
- Sven Nelander
- Department of Immunology Genetics and Pathology, Uppsala University
- Denise Sheer
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Catherine L. R. Merry
- Stem Cell Glycobiology Group, Biodiscovery Institute, University of Nottingham
- Federica Marelli-Berg
- The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- Sebastian Brandner
- Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust
- Silvia Marino
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London
- DOI
- https://doi.org/10.1038/s41467-021-26297-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 20
Abstract
The identification of patient-specific disease mechanisms and druggable targets is crucial for precision medicine in glioblastoma. Here, the authors show that comparing patients-matched glioma-initiating cells with neural stem cells enables the discovery of patient-specific mechanisms of disease and the identification of effective drugs
